Category: Pα+ - Psychedelic Alpha

New: Explore the psychedelic pipeline via our Q3'25 🎯 Bullseye Charts.

Read more about the article Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai Scores $11.4M NIDA Grant; First Look at Real-World Outcomes from Oregon Psilocybin Clients; Pipeline Updates

Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai Scores $11.4M NIDA Grant; First Look at Real-World Outcomes from Oregon Psilocybin Clients; Pipeline Updates

Post published:September 24, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

Post published:September 22, 2025
Post category:Analysis News Pα+

Read more about the article UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

Post published:September 19, 2025
Post category:Analysis News Pα+

Read more about the article ‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

Post published:September 11, 2025
Post category:Interviews Pα+

Read more about the article August 2025 Psychedelic Patent Update

August 2025 Psychedelic Patent Update

Post published:September 9, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Post published:September 8, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

Post published:September 5, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Post published:September 3, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation

Post published:August 28, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

Post published:August 25, 2025
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.